Adagene partners with Merck on combination treatment for cancer
Adagene has signed a clinical trial collaboration and supply agreement with Merck (MSD) to assess its drug candidates, ADG116 and ADG126, in combination with the…
Latest Deals
-
ParexelMergers & Acquisitions $8.5BN
-
ICONMergers & Acquisitions $12BN
-
BEKHealthCapital Raising $4M
-
Hawthorne EffectCapital Raising $20M
-
ParexelMergers & Acquisitions $8.5BN
-
ICONMergers & Acquisitions $12BN
-
BEKHealthCapital Raising $4M
-
Hawthorne EffectCapital Raising $20M
Pharma Sector All Deal Activity by Value and Volume (Last 12 months)
Pharma Sector Overall Deal Activity by Region (Last 12 months)
Top Deals in Pharma Sector (Last 12 months)
| Acquirer/Investor | Issuer / Partner / Target | Deal Date | Value (US$m) |
|---|---|---|---|
| AstraZeneca | Alexion Pharmaceuticals | 12 Dec 2020 | 39,000.0 |
| The Blackstone Group , The Carlyle Group ., Hellman & Friedman , GIC Pvt | Medline Industries | 05 Jun 2021 | 34,000.0 |
| Gilead Sciences | Immunomedics | 13 Sep 2020 | 21,000.0 |
| Thermo Fisher Scientific | PPD | 15 Apr 2021 | 20,900.0 |
| Siemens Healthineers | Varian Medical Systems | 02 Aug 2020 | 16,400.0 |
| Soaring Eagle Acquisition | Ginkgo BioWorks | 11 May 2021 | 15,000.0 |
| Bristol-Myers Squibb | MyoKardia | 05 Oct 2020 | 13,100.0 |
| Thermo Fisher Scientific | Qiagen | 13 Aug 2020 | 12,500.0 |
| ICON | PRA Health Sciences | 24 Feb 2021 | 12,000.0 |
| Danaher | Aldevron | 17 Jun 2021 | 9,600.0 |
Top Pharma Sector Advisors (2020 Vs. 2019)
Top Financial Advisors – All Deals
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Centerview Partners | 1 | 9 |
| Morgan Stanley | 2 | 1 |
| The Goldman Sachs Group | 3 | 4 |
| Bank of America Corp | 4 | 10 |
| JPMorgan Chase & Co | 5 | 14 |
| Evercore | 6 | 3 |
| Lazard | 7 | 18 |
| Ondra | 8 | 67 |
| J.P. Morgan Securities | 9 | 2 |
| Cowen & Company, . | 10 | N/A |
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Jefferies | 1 | 8 |
| The Goldman Sachs Group | 2 | 2 |
| Cowen | 3 | 32 |
| Centerview Partners | 4 | 4 |
| Bank of America Corp | 5 | 9 |
| SVB Financial Group | 6 | 12 |
| Morgan Stanley | 7 | 1 |
| Rothschild & Co SCA | 8 | 5 |
| Evercore | 9 | 7 |
| Barclays Plc | 10 | 23 |
Top Legal Advisors – All Deals
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Wachtell, Lipton, Rosen & Katz | 1 | 3 |
| Fried, Frank, Harris, Shriver & Jacobson | 2 | 19 |
| Goodwin Procter | 3 | 20 |
| Freshfields Bruckhaus Deringer | 4 | 16 |
| Allen & Overy | 5 | 62 |
| Latham & Watkins | 6 | 21 |
| Simmons & Simmons | 7 | 172 |
| Sullivan & Cromwell | 8 | 15 |
| Davis Polk & Wardwell | 9 | 2 |
| Cravath, Swaine & Moore | 10 | 18 |
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Goodwin Procter | 1 | 2 |
| Wilson Sonsini Goodrich & Rosati | 2 | 22 |
| Latham & Watkins | 3 | 1 |
| Cooley | 4 | 5 |
| Ropes & Gray | 5 | 7 |
| Kirkland & Ellis | 6 | 4 |
| Baker & McKenzie | 7 | 12 |
| Morgan, Lewis & Bockius | 8 | 23 |
| Jones Day | 9 | 3 |
| Dechert | 10 | 54 |
Pharma Sector Mergers & Acquisitions Deal Activity by Value and Volume (Last 12 months)
Pharma Sector Mergers & Acquisitions by Region (Last 12 months)
Top Mergers & Acquisitions in Pharma Sector (Last 12 months)
| Acquirer/Investor | Issuer / Partner / Target | Deal Date | Value (US$m) | AstraZeneca | Alexion Pharmaceuticals | 12 Dec 2020 | 39,000.0 | Gilead Sciences | Immunomedics | 13 Sep 2020 | 21,000.0 | Thermo Fisher Scientific | PPD | 15 Apr 2021 | 20,900.0 | Siemens Healthineers | Varian Medical Systems | 02 Aug 2020 | 16,400.0 | Soaring Eagle Acquisition | Ginkgo BioWorks | 11 May 2021 | 15,000.0 | Bristol-Myers Squibb | MyoKardia | 05 Oct 2020 | 13,100.0 | Thermo Fisher Scientific | Qiagen | 13 Aug 2020 | 12,500.0 | ICON | PRA Health Sciences | 24 Feb 2021 | 12,000.0 | Danaher | Aldevron | 17 Jun 2021 | 9,600.0 | Jazz Pharmaceuticals | GW Pharmaceuticals | 03 Feb 2021 | 7,200.0 |
|---|
Top Pharma Sector Advisors (2020 Vs. 2019)
Top Financial Advisors - Mergers & Acquisitions Deals
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Centerview Partners | 1 | 9 |
| Morgan Stanley | 2 | 1 |
| The Goldman Sachs Group | 3 | 4 |
| Bank of America Corp | 4 | 12 |
| JPMorgan Chase & Co | 5 | 13 |
| Evercore | 6 | 3 |
| Lazard | 7 | 15 |
| Ondra | 8 | 49 |
| Cowen & Company, . | 9 | N/A |
| Mizuho Financial Group | 10 | N/A |
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Centerview Partners | 1 | 4 |
| The Goldman Sachs Group | 2 | 2 |
| Bank of America Corp | 3 | 6 |
| Jefferies | 4 | 5 |
| Lazard | 5 | 3 |
| Morgan Stanley | 6 | 1 |
| JPMorgan Chase & Co | 7 | 17 |
| Evercore | 8 | 8 |
| Barclays Plc | 9 | 23 |
| Stifel Financial Corp | 10 | 48 |
Top Legal Advisors - Mergers & Acquisitions Deals
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Wachtell, Lipton, Rosen & Katz | 1 | 3 |
| Fried, Frank, Harris, Shriver & Jacobson | 2 | 18 |
| Goodwin Procter | 3 | 19 |
| Freshfields Bruckhaus Deringer | 4 | 20 |
| Allen & Overy | 5 | 65 |
| Simmons & Simmons | 6 | 126 |
| Sullivan & Cromwell | 7 | 15 |
| Latham & Watkins | 8 | 22 |
| Davis Polk & Wardwell | 9 | 2 |
| Cravath, Swaine & Moore | 10 | 17 |
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Goodwin Procter | 1 | 1 |
| Cooley | 2 | 3 |
| Morgan, Lewis & Bockius | 3 | 12 |
| Latham & Watkins | 4 | 2 |
| Wilson Sonsini Goodrich & Rosati | 5 | 16 |
| White & Case | 6 | 23 |
| Skadden, Arps, Slate, Meagher & Flom & Affiliates | 7 | 4 |
| Ropes & Gray | 8 | 15 |
| Gibson, Dunn & Crutcher | 9 | 22 |
| Kirkland & Ellis | 10 | 6 |
Pharma Sector Private Equity Deal Activity by Value and Volume (Last 12 months)
Pharma Sector Private Equity Deals by Region (Last 12 months)
Top Private Equity Deals in Pharma Sector (Last 12 months)
| Acquirer/Investor | Issuer / Partner / Target | Deal Date | Value (US$m) | The Blackstone Group , The Carlyle Group ., Hellman & Friedman , GIC Pvt | Medline Industries | 05 Jun 2021 | 34,000.0 | Permira Advisers | LivaNova | 04 Mar 2021 | 3,700.0 | EQT IX Fund | Recipharm | 14 Dec 2020 | 2,116.9 | Nordic Capital | Advanz Pharma | 27 Jan 2021 | 1,920.1 | Permira | neuraxpharm Arzneimittel | 22 Sep 2020 | 1,877.5 | Altaris Capital Partners | Generic Rx Pharma Business | 01 Mar 2021 | 1,550.0 | Pamplona Capital Management , Triton Investment Management Limited, CVC Capital Partners SICAV-FIS SA, Bain Capital , BC Partners | Mediq | 21 Oct 2020 | 1,416.3 | PAI Partners | SGD | 25 Mar 2021 | 1,182.0 | Rock Springs Capital Management , Casdin Capital | Exact Sciences | 27 Oct 2020 | 869.2 | Columbia Threadneedle Investments, TPG Sixth Street Partners, First Light Asset Management, , Rock Springs Capital Management , Eaton Vance Corp, Silver Lake Management , Millennium Management , Orbimed Advisors , ClearBridge Investments, , Tudor Investment Corporation, Coatue Management , T Rowe Price Associates , Fidelity Management & Research Company, Highland Capital Management, L.P, Pura Vida Investments , Canada Pension Plan Investment Board | Caris Life Sciences | 11 May 2021 | 830.0 |
|---|
Top Pharma Sector Advisors (2020 Vs. 2019)
Top Financial Advisors – Private Equity Deals
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Rothschild & Co SCA | 1 | 1 |
| Deloitte Touche Tohmatsu | 2 | 23 |
| Carnegie Holding AB | 3 | N/A |
| Goldman Sachs International | 4 | N/A |
| Jefferies International | 5 | N/A |
| Ernst & Young Global | 6 | 31 |
| PricewaterhouseCoopers International | 7 | 2 |
| UBS Group AG | 8 | 3 |
| Jefferies | 9 | 48 |
| Evercore | 10 | 15 |
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Jefferies | 1 | 49 |
| SVB Financial Group | 2 | 35 |
| Rothschild & Co SCA | 3 | 2 |
| Carnegie Holding AB | 4 | N/A |
| Cowen | 5 | N/A |
| Deloitte Touche Tohmatsu | 6 | 7 |
| Evercore | 7 | 6 |
| Barclays Plc | 8 | 14 |
| Van Lanschot Kempen NV | 9 | N/A |
| Ernst & Young Global | 10 | 9 |
Top Legal Advisors – Private Equity Deals
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Ropes & Gray | 1 | 17 |
| Latham & Watkins | 2 | 10 |
| Uria Menendez Abogados S | 3 | N/A |
| Goodwin Procter | 4 | 28 |
| Clifford Chance | 5 | 41 |
| Roschier Attorneys | 6 | 38 |
| Setterwalls Advokatbyra AB | 7 | N/A |
| Allen & Overy | 8 | 53 |
| Linklaters | 9 | 5 |
| Ashurst | 10 | 7 |
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Latham & Watkins | 1 | 1 |
| Goodwin Procter | 2 | 35 |
| Ropes & Gray | 3 | 3 |
| Uria Menendez Abogados S | 4 | N/A |
| Baker & McKenzie | 5 | N/A |
| Kirkland & Ellis | 6 | 2 |
| DLA Piper | 7 | N/A |
| Dechert | 8 | 34 |
| Paul, Weiss, Rifkind, Wharton & Garrison | 9 | 16 |
| Wilmer Cutler Pickering Hale and Dorr | 10 | 37 |
Pharma Sector Venture Financing Deal Activity by Value and Volume (Last 12 months)
Pharma Sector Venture Financing Deals by Region (Last 12 months)
Top Venture Financing Deals in Pharma Sector (Last 12 months)
| Acquirer/Investor | Issuer / Partner / Target | Deal Date | Value (US$m) | FutureX Capital, Qingdao Guoxin Financial Holding , Shenzhen Fu Rong lusive Finance , Hillhouse Capital Group | Kangfeng Biotechnology (Shanghai) | 22 Feb 2021 | 1,078.9 | GV Management , New Enterprise Associates , 8VC, ARCH Venture Partners | National Resilience | 23 Nov 2020 | 750.0 | Itochu Technology Ventures, ., Invus Group , Emerson Collective , EcoR1 Capital , Vertex Ventures HC, F2 Ventures Limited, Matrix Capital Management Fund , Surveyor Capital , Redmile Group , SoftBank Vision Fund , Fidelity Management & Research Company, EDBI Pte , Samsara BioCapital , MPM Capital | ElevateBio | 15 Mar 2021 | 525.0 | Andreessen Horowitz , Nextech Invest , Casdin Capital , ARCH Venture Partners , Section 32, Arboretum Ventures , GV Management | EQRx | 11 Jan 2021 | 500.0 | Baupost Group, FirstMark Capital , Altimeter Capital Management , SignalFire Management Services, , Radcliff Group, TQ Ventures , General Catalyst Partners , BoxGroup, ShawSpring Partners, , Dragoneer Investment Group , Torch Capital, 776 Fund Management | Ro-co | 23 Mar 2021 | 500.0 | Temasek Holdings (Private) , Two Sigma Ventures , GV Management , Alexandria Venture Investments, Foresite Capital Management , Third Rock Ventures , SoftBank Investment Advisors, BlackRock , T Rowe Price Associates , Andreessen Horowitz , ARCH Venture Partners , Canada Pension Plan Investment Board, Casdin Capital , HOF Capital | Insitro | 15 Mar 2021 | 400.0 | Premji Invest, Orbimed Advisors , Population Health Partners , GV Management , Foresite Capital Management , Federated Hermes , Mithril Capital Management , RA Capital Management , Redmile Group , ArrowMark Partners, Polaris Partners , Adimab , Omega Fund Management , Fidelity Management & Research | Adagio Therapeutics | 19 Apr 2021 | 336.0 | SoftBank Capital, CMB International Capital Management (Shenzhen) Co., ., Morningside Venture Capital Group, IMO Ventures, ., Sequoia China Fund, Oceanpine Capital, SIG Asia Investments, L, CICC Capital Management Limited, PICC Capital Investment Management Limited, Shunwei Capital Partners, Fangyuan Capital, Parkway Capital Investors, , Mirae Asset Global Investments , Citic Capital Partners, Tencent Holdings | XtalPi | 28 Sep 2020 | 318.8 | Central Enterprise Poverty Area Industrial Investment Fund , China Merchants Securities , Huatai Securities , Tianjin Liren Investment Management | Shenzhen Huada Gene | 09 Feb 2021 | 310.3 | Casdin Capital , RA Capital Group, Vida Ventures , T Rowe Price Associates , Tybourne Capital Management (HK), ., Perceptive Advisors , BlackRock , Venrock Healthcare Capital Partners , Viking Global Investors , Logos Global Management , Wellington Management , Pfizer Venture Investments, Farallon Capital Management , SDIC China Merchants Investment Management Co., , Sphera Global Healthcare Master Fund | LianBio | 29 Oct 2020 | 310.0 |
|---|
All markets data shared in the dashboard is copyright of GlobalData PLC and is subject to the GlobalData Terms & Conditions. Content in the dashboard should not be viewed as a recommendation and should not be relied upon to make investment decisions. We make every effort to ensure our content is accurate and to correct mistakes as soon as possible. If you spot an error please email editorialenquiries@globaldata.com. Further information about our editorial standards and complaints procedure is available here. GlobalData is not responsible for the use of any content outside the scope of the GlobalData Terms & Conditions.
Latest News
View More
eFFECTOR begins dosing in Phase Ib trial of zotatifin in Covid-19
eFFECTOR Therapeutics has dosed the first participant in the Phase Ib clinical trial of zotatifin (eFT226) to treat outpatients with mild to moderate Covid-19. The…
Humanigen’s partners get approval to trial lenzilumab in South Korea
South Korea’s Ministry of Food and Drug Safety (MFDS) has granted approval to Humanigen’s partners, Telcon RF Pharmaceutical and KPM…
Sorrento doses subjects in Covid-19 trial of intranasal drug in the UK
Sorrento Therapeutics has dosed subjects in Phase II trial of its intranasal drug, COVIDROPS, for the treatment of Covid-19 in…
FAU team develops new method to forecast Covid-19 trial outcome
A research team at Florida Atlantic University (FAU)’s College of Engineering and Computer Science in the US has created a…
FDA places clinical hold on Magenta’s Phase I/II leukaemia trial
The US Food and Drug Administration (FDA) has issued a clinical hold letter for Magenta Therapeutics’ investigational new drug application…
Company A-Z
View More
GlobalData
GlobalData exists to help businesses decode the future to profit from faster, more informed decisions.
